Malingering, deliberately feigning or exaggerating symptoms appears to be rising. This shift brings with it a tangled web of clinical, operational, and ethical challenges that affect not only providers but also the patients most in need of timely, effective care.
We now have the ability to diagnose and treat with data-driven insights and deliver measurable outcomes. It’s on us as providers to ensure that we are consistently adopting the latest, proven technology and treatment modalities that can benefit our patients.
Richard Fu details the company's approach to nutrition therapy and strategy for patients using GLP-1s.
By moving beyond subjective and heterogeneous criteria and embracing objective brain function measures, the field of psychiatry can achieve greater precision and efficacy in addressing complex disorders.
Through a new partnership, employees of BetterHelp’s employer clients can access Talkiatry’s psychiatry services on an in-network basis at no extra cost.
A Health Affairs study discovered that nearly two-thirds of Medicare Advantage psychiatrist networks, or 64.6%, were narrow in 2019. Comparatively, about 43.1% of Medicaid managed care networks were narrow and 39.5% of ACA Marketplaces were narrow.
Talkiatry is now available to Horizon Healthcare Services’ commercial members at no additional cost, giving 3.6 million people access to the virtual mental health services. The company treats patients ages 5 years and older for conditions including anxiety, depression and bipolar disorder.
How Apella leverages technology to increase OR efficiency.
A California law signed Oct. 8 by Gov. Gavin Newsom requires that mental health and substance abuse patients be offered return appointments no more than 10 days after a previous session, unless their provider OKs less frequent visits.
Access to mental healthcare continues to be a hurdle amid the Covid-19 pandemic, prompting Aetna and telehealth provider Inpathy to expand their existing mental health partnership to include three more states.
The company said the decision to cancel the advisory committee meeting for lumateperone was made so the agency would have additional time to review information the firm had provided regarding the drug.
Nuplazid, which is FDA-approved for Parkinson's psychosis, failed to fully improve symptoms as an adjunctive treatment for schizophrenia.
Dickon Waterfield discusses why Lantern's navigation works.
The company's shares fell more than 20 percent Monday on data from the trials of lumateperone, but an analyst wrote that the reason for the high placebo response rate that led to one trial's failure remains unclear.
Interest and investment in the online therapy space has been ramping up as the technology has been positioned as a lever to address the larger issue of expanding access to behavioral health resources.
An analyst said the news could negatively affect shares of a successor to the company that developed rapastinel - which Allergan bought in 2015 - given that its drugs belong to the same class.
Talkspace's first chief medical officer Neil Leibowitz talked about the online therapy providers' ambitions to move into psychiatry by the end of the year.
With the deal, purchaser Genoa, a QoL Healthcare Company, has launched a new telemedicine division, Genoa Telepsychiatry.